Nuclear DNA is the target responsible for anticancer activity of platinum anticancer drugs. Their activity is mediated by altered signals related to programmed cell death and the activation of various signaling pathways. An example is activation of nuclear factor kappaB (NF-κB). Binding of NF-κB proteins to their consensus sequences in DNA (κB sites) is the key biochemical activity responsible for the biological functions of NF-κB. Using gel-mobility-shift assays and surface plasmon resonance spectroscopy we examined the interactions of NF-κB proteins with oligodeoxyribonucleotide duplexes containing κB site damaged by DNA adducts of three platinum complexes. These complexes markedly differed in their toxic effects in tumor cells and comprised highly cytotoxic trinuclear platinum(II) complex BBR3464, less cytotoxic conventional cisplatin and ineffective transplatin. The results indicate that structurally different DNA adducts of these platinum complexes exhibit a different efficiency to affect the affinity of the platinated DNA (κB sites) to NF-κB proteins. Our results support the hypothesis that structural perturbations induced in DNA by platinum(II) complexes correlate with their higher efficiency to inhibit binding of NF-κB proteins to their κB sites and cytotoxicity as well. However, the full generalization of this hypothesis will require to evaluate a larger series of platinum(II) complexes.

Department of Biophysics Faculty of Science Palacky University Slechtitelu 27 CZ 78371 Olomouc Czech Republic

Department of Chemistry Virginia Commonwealth University Richmond VA 23284 2006 USA

Institute of Biophysics Academy of Sciences of the Czech Republic v v i Kralovopolska 135 CZ 61265 Brno Czech Republic

Zobrazit více v PubMed

Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature Rev. Cancer 7, 573–584 (2007). PubMed

Johnson N. P. et al.. Metal antitumor compounds: The mechanism of action of platinum complexes. Prog. Clin. Biochem. Med. 10, 1–24 (1989).

Jamieson E. R. & Lippard S. J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99, 2467–2498 (1999). PubMed

Fuertes M. A., Alonso C. & Perez J. M. Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev. 103, 645–662 (2003). PubMed

Oiso S. et al.. Involvement of NF-kappa B activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells. Oncol. Rep. 28, 27–32 (2012). PubMed

Luo J.-L., Kamata H. & Karin M. The anti-death machinery in IKK/NF-kappa B signaling. J. Clin. Immunol. 25, 541–550 (2005). PubMed

Dutta J., Fan Y., Gupta N., Fan G. & Gelinas C. Current insights into the regulation of programmed cell death by NF-kappa B. Oncogene 25, 6800–6816 (2006). PubMed

Smale S. T. Hierarchies of NF-kB target-gene regulation. Nature Immunol. 12, 689–694 (2011). PubMed PMC

Hayden M. S. & Ghosh S. NF-kB, the first quarter-century: remarkable progress and outstanding questions. Genes & Dev 26, 203–234 (2012). PubMed PMC

Kasparkova J. et al.. Different affinity of NF-kB proteins to DNA modified by antitumor cisplatin and its clinically ineffective trans isomer. FEBS J. 281, 1393–1408 (2014). PubMed

Martone R. et al.. Distribution of NF-kB-binding sites across human chromosome 22. Proc. Natl. Acad. Sci. USA 100, 12247–12252 (2003). PubMed PMC

Natoli G., Saccani S., Bosisio D. & Marazzi I. Interactions of NF-kB with chromatin: the art of being at the right place at the right time. Nat. Immunol. 6, 439–445 (2005). PubMed

Chen F. E., Huang D. B., Chen Y. Q. & Ghosh G. Crystal structure of p50/p65 heterodimer of transcription factor NF-kappa B bound to DNA. Nature 391, 410–413 (1998). PubMed

Huang D.-B., Phelps C. B., Fusco A. J. & Ghosh G. Crystal structure of a free kB DNA: Insights into DNA recognition by transcription factor NF-kB. J. Mol. Biol. 346, 147–160 (2005). PubMed

Farrell N. In Metal Ions in Biological Systems Vol. 42 (eds Sigel A. & Sigel H.) 251–296 (Marcel Dekker, Inc., 2004). PubMed

Billecke C. et al.. Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma. Neuro-Oncol. 8, 215–226 (2006). PubMed PMC

Mangrum J. B. & Farrell N. P. Excursions in polynuclear platinum DNA binding. Chem. Commun. 46, 6640–6650 (2010). PubMed PMC

Pratesi G. et al.. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Brit. J. Cancer 80, 1912–1919 (1999). PubMed PMC

Riccardi A. et al.. In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma. Cancer Chemother. Pharmacol. 47, 498–504 (2001). PubMed

Fichtinger-Schepman A. M. J., Van der Veer J. L., Den Hartog J. H. J., Lohman P. H. M. & Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: Formation, identification, and quantitation. Biochemistry 24, 707–713 (1985). PubMed

Brabec V. et al.. DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent. Biochemistry 38, 6781–6790 (1999). PubMed

Zehnulova J., Kasparkova J., Farrell N. & Brabec V. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464. J. Biol. Chem. 276, 22191–22199 (2001). PubMed

Kasparkova J., Zehnulova J., Farrell N. & Brabec V. DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair. J. Biol. Chem. 277, 48076–48086 (2002). PubMed

Wan F. et al.. Ribosomal protein S3: A KH domain subunit in NF-kB complexes that mediates selective gene regulation. Cell 131, 927–939 (2007). PubMed

Wan F. & Lenardo M. J. Specification of DNA binding activity of NF-kB proteins. Cold Spring Harb. Perspect. Biol. 1, a000067 (2009). PubMed PMC

Sathe S. S. et al.. Mutant human cells with constitutive activation of NF-kB. Proc. Natl. Acad. Sci. USA 101, 192–197 (2004). PubMed PMC

Schubert F., Zettl H., Hafner W., Krauss G. & Krausch G. Comparative thermodynamic analysis of DNA-protein interactions using surface plasmon resonance and fluorescence correlation spectroscopy. Biochemistry 42, 10288–10294 (2003). PubMed

Lin K.-C., Wey M.-T., Kan L.-S. & Shiuan D. Characterization of the interactions of lysozyme with DNA by surface plasmon resonance and circular dichroism spectroscopy. Appl. Biochem. Biotechnol. 158, 631–641 (2009). PubMed

Muller C. W., Rey F. A., Sodeoka M., Verdine G. L. & Harrison S. C. Structure of the NF-kB p50 homodimer bound to DNA. Nature 373, 311–317 (1995). PubMed

Brabec V. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog. Nucleic Acid Res. Mol. Biol. 71, 1–68 (2002). PubMed

Brabec V., Sip M. & Leng M. DNA conformational distortion produced by site-specific interstrand cross-link of trans-diamminedichloroplatinum(II). Biochemistry 32, 11676–11681 (1993). PubMed

Qu Y., Scarsdale N. J., Tran M. C. & Farrell N. P. Cooperative effects in long-range 1,4 DNA-DNA interstrand cross-links formed by polynuclear platinum complexes: an unexpected syn orientation of adenine bases outside the binding sites. J. Biol. Inorg. Chem. 8, 19–28 (2003). PubMed

Hegmans A. et al.. Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex. Minor groove pre-association affects kinetics and mechanism of cross-link formation as well as adduct structure. J. Am. Chem. Soc. 126, 2166–2180 (2004). PubMed

Cox J. W., Berners-Price S., Davies M. S., Qu Y. & Farrell N. Kinetic analysis of the stepwise formation of a long-range DNA interstrand cross-link by a dinuclear platinum antitumor complex: Evidence for aquated intermediates and formation of both kinetically and thermodynamically controlled conformers. J. Am. Chem. Soc. 123, 1316–1326 (2001). PubMed

Kasparkova J., Farrell N. & Brabec V. Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes. J. Biol. Chem. 275, 15789–15798 (2000). PubMed

Taylor B. S. et al.. Multiple NF-kB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J. Biol. Chem. 273, 15148–15156 (1998). PubMed

Fujita T., Nolan G. P., Ghosh S. & Baltimore D. Independent modes of transcriptional activation by the p50-subunit and p65-subunit of NF-kappa-B. Genes Dev. 6, 775–787 (1992). PubMed